Kerri Fitzgerald

DocwireNews

The U.S. Food and Drug Administration (FDA) requested that Allergan voluntarily recall its BIOCELL textured breast implants and tissue expanders following <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-lymphoma-breast-implants/">reports of an increased risk of breast implant-associated anaplastic large cell lymphoma&nbsp;</a>(BIA-ALCL). Allergan agreed and is removing these products from the global market.&nbsp;Thirty-eight other countries have already recalled the implants.<a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl-an-overview-of-presentation-and-pathogenesis-and-guidelines-for-pathological-diagnosis-and-management/">The FDA&rsquo;s request was based on a recent worldwide report</a> that indicated 573 unique BIA-ALCL cases, including 33 patient deaths. Of the total BIA-ALCL cases, 481 reportedly occurred in women with Allergan breast implants at the time of diagnosis. In addition, 12 deaths occurred in patients with these implants; the manufacturer or texture was unknown for 20 of the other deaths.&ldquo;Based on the currently available information, including the newly submitted data, our analysis demonstrates that the risk of BIA-ALCL with Allergan BIOCELL textured implants is approximately six times the risk of BIA-ALCL with textured implants from other manufacturers marketing in the United States, and continued distribution of Allergan&rsquo;s Biocell BIOCELL textured breast implants would likely cause serious, adverse health consequences and potentially death from BIA-ALCL,&rdquo; the agency noted in a press release.The FDA does not recommend that asymptomatic women with textured breast implants have them removed. Symptoms of BIA-ALCL include swelling, pain, and skin irritation. The FDA said it will continue to evaluate any new information and may take action against other breast implants, if needed.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Do you have <a href="https://twitter.com/hashtag/breastimplants?src=hash&amp;ref_src=twsrc%5Etfw">#breastimplants</a> or know someone who has <a href="https://twitter.com/hashtag/breast?src=hash&amp;ref_src=twsrc%5Etfw">#breast</a> <a href="https://twitter.com/hashtag/implants?src=hash&amp;ref_src=twsrc%5Etfw">#implants</a>?
A very rare <a href="https://twitter.com/hashtag/cancer?src=hash&amp;ref_src=twsrc%5Etfw">#cancer</a> has been reported associated with breast implants, called breast implant-associated anaplastic large cell <a href="https://twitter.com/hashtag/lymphoma?src=hash&amp;ref_src=twsrc%5Etfw">#lymphoma</a>, or <a href="https://twitter.com/hashtag/BIA?src=hash&amp;ref_src=twsrc%5Etfw">#BIA</a>-ALCL. Read the FDA warning here: <a href="https://t.co/rUDGFfwvTE">https://t.co/rUDGFfwvTE</a> <a href="https://t.co/IfxOr1bRq6">pic.twitter.com/IfxOr1bRq6</a>
&mdash; Gary Goldman, MD (@GaryGoldmanMD) <a href="https://twitter.com/GaryGoldmanMD/status/1144334849819467779?ref_src=twsrc%5Etfw">June 27, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><h2>FDA recommendations</h2>The FDA recommended the following information for healthcare providers:<ul>
<li>You should immediately stop implanting Allergan BIOCELL breast implants and work with your facility to return existing inventory.</li>
<li>At this time, the FDA does not recommend removal of these or other types of breast implants in patients who have no symptoms due to the low risk of developing BIA-ALCL.</li>
<li>You should inform your patients about the risk of developing BIA-ALCL and what to look for.</li>
<li>Prior to implantation of any breast implant, provide your patients with the manufacturer&rsquo;s patient labeling, as well as any other educational materials, and discuss the benefits and risks of the different types of implants.</li>
<li>Consider the possibility of BIA-ALCL when treating a patient with late onset, peri-implant changes. In some cases, patients presented with a seroma, mass, hardening adjacent to the breast implant. If you have a patient with suspected BIA-ALCL, ensure an evaluation is conducted by experts familiar with the diagnosis and treatment of BIA-ALCL.</li>
<li>Collect fresh seroma fluid and representative portions of the capsule and send for pathology tests to rule out BIA-ALCL. Diagnostic evaluation should include cytological evaluation of seroma fluid or mass with Wright Giemsa stained smears and cell block immunohistochemistry/flow cytometry testing for cluster of differentiation and anaplastic lymphoma kinase markers.</li>
<li>Develop an individualized treatment plan considering current clinical practice guidelines, such as those from the&nbsp;<a href="https://academic.oup.com/asj/article/39/Supplement_1/S3/5304919">Plastic Surgery Foundation of the National Comprehensive Cancer Network (NCCN)</a><a href="http://www.fda.gov/about-fda/website-policies/website-disclaimer">External Link Disclaimer</a>&nbsp;when choosing your treatment approach.</li>
<li>Report all cases of BIA-ALCL in individuals with breast implants to&nbsp;<a href="https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home">MedWatch, the FDA Safety Information and Adverse Event Reporting program</a>.</li>
<li>Healthcare personnel employed by facilities that are subject&nbsp;<a href="https://www.fda.gov/medical-devices/postmarket-requirements-devices/mandatory-reporting-requirements-manufacturers-importers-and-device-user-facilities">to the FDA&rsquo;s user facility reporting requirements</a>&nbsp;should follow the reporting procedures established by their facilities. Prompt reporting of adverse events can help the FDA identify and better understand the risks associated with medical devices. In some cases, the FDA may contact you for additional information. The FDA will keep the identities of personnel reporting the event and the patient confidential.</li>
<li>Submit case reports of BIA-ALCL to the&nbsp;<a href="https://www.thepsf.org/research/registries/profile">Patient Registry and Outcomes For breast Implants and anaplastic large cell Lymphoma etiology and Epidemiology (PROFILE) Registry</a><a href="http://www.fda.gov/about-fda/website-policies/website-disclaimer">External Link Disclaimer</a>&nbsp;to contribute to a better understanding of the causes and treatments of BIA-ALCL.</li>
</ul>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

FDA Requests Global Recall of Textured Breast Implants Associated With Cancer

Oncology

The U.S. Food and Drug Administration (FDA) requested that Allergan voluntarily recall its BIOCELL textured breast implants and tissue expanders 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe